Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).

Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Van Cutsem E, Scheithauer W, Lutz MP, Nordlinger B; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK (CRUK); Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD).

Ann Surg. 2012 Mar;255(3):534-9. doi: 10.1097/SLA.0b013e3182456aa2.

PMID:
22314329
2.

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD).

Lancet. 2008 Mar 22;371(9617):1007-16. doi: 10.1016/S0140-6736(08)60455-9.

3.

Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.

Tanis E, Julié C, Emile JF, Mauer M, Nordlinger B, Aust D, Roth A, Lutz MP, Gruenberger T, Wrba F, Sorbye H, Bechstein W, Schlag P, Fisseler A, Ruers T.

Eur J Cancer. 2015 Nov;51(17):2708-17. doi: 10.1016/j.ejca.2015.08.014. Epub 2015 Sep 2.

PMID:
26342674
4.

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und–tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD).

Lancet Oncol. 2013 Nov;14(12):1208-15. doi: 10.1016/S1470-2045(13)70447-9. Epub 2013 Oct 11.

PMID:
24120480
5.

Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.

Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN.

Ann Surg. 2012 Oct;256(4):642-50. doi: 10.1097/SLA.0b013e31826b4dcc.

6.

Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).

Schwarz L, Michel P, Scotté M.

Ann Surg. 2015 Jan;261(1):e28-9. doi: 10.1097/SLA.0000000000000419. No abstract available.

PMID:
24263311
7.

Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.

Yi JH, Kim H, Jung M, Shin SJ, Choi JS, Choi GH, Baik SH, Min BS, Kim NK, Ahn JB.

Oncology. 2013;85(5):283-9. doi: 10.1159/000355475. Epub 2013 Nov 6.

PMID:
24217184
8.

Reply to letter: "Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)".

Sorbye H, Mauer M, Nordlinger B.

Ann Surg. 2015 Jan;261(1):e29. doi: 10.1097/SLA.0000000000000659. No abstract available.

PMID:
24646558
9.

Perioperative chemotherapy for resectable hepatic metastases.

Kopetz S, Vauthey JN.

Lancet. 2008 Mar 22;371(9617):963-5. doi: 10.1016/S0140-6736(08)60429-8. No abstract available.

PMID:
18358910
10.

Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).

Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP.

J Clin Oncol. 2012 Oct 10;30(29):3596-603. doi: 10.1200/JCO.2012.42.6031. Epub 2012 Sep 10.

PMID:
22965965
11.

What is the standard chemotherapy for colorectal cancer patients with resectable liver metastases?

O'Neil BH, Goldberg RM.

Nat Clin Pract Oncol. 2009 Jan;6(1):14-6. doi: 10.1038/ncponc1274. Epub 2008 Nov 11. No abstract available.

PMID:
19002130
12.

Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases.

Rubie C, Frick VO, Ghadjar P, Wagner M, Justinger C, Graeber S, Sperling J, Kollmar O, Schilling MK.

World J Gastroenterol. 2011 Jul 14;17(26):3109-16. doi: 10.3748/wjg.v17.i26.3109.

13.

The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis.

Scartozzi M, Siquini W, Galizia E, Stortoni P, Marmorale C, Berardi R, Fianchini A, Cascinu S.

Dig Liver Dis. 2011 Mar;43(3):194-8. doi: 10.1016/j.dld.2010.07.003. Epub 2010 Aug 21.

PMID:
20728416
14.

Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer.

Nagai Y, Beppu T, Sakamoto Y, Miyamoto Y, Hayashi H, Nitta H, Imai K, Masuda T, Okabe H, Hirashima K, Imamura Y, Baba Y, Chikamoto A, Baba H.

Anticancer Res. 2014 Oct;34(10):5529-35.

PMID:
25275051
15.

FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.

Beppu T, Hayashi N, Masuda T, Komori H, Horino K, Hayashi H, Okabe H, Baba Y, Kinoshita K, Akira C, Watanebe M, Takamori H, Baba H.

Anticancer Res. 2010 Mar;30(3):1015-20.

PMID:
20393029
16.

Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.

Dexiang Z, Li R, Ye W, Haifu W, Yunshi Z, Qinghai Y, Shenyong Z, Bo X, Li L, Xiangou P, Haohao L, Lechi Y, Tianshu L, Jia F, Xinyu Q, Jianmin X.

Ann Surg Oncol. 2012 Sep;19(9):2860-8. doi: 10.1245/s10434-012-2356-9. Epub 2012 Apr 12.

PMID:
22526903
17.

Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.

Yuste AL, Aparicio J, Segura A, López-Tendero P, Gironés R, Pérez-Fidalgo JA, Díaz R, Calderero V.

Clin Colorectal Cancer. 2003 Feb;2(4):231-4.

PMID:
12620142
18.

Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis.

Faron M, Chirica M, Tranchard H, Balladur P, de Gramont A, Afchain P, Andre T, Paye F.

J Gastrointest Cancer. 2014 Sep;45(3):298-306. doi: 10.1007/s12029-014-9594-y.

PMID:
24610400
19.

Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.

Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jäger D, Büchler MW, Weitz J, Koch M.

BMC Cancer. 2014 Mar 11;14:174. doi: 10.1186/1471-2407-14-174.

20.

Artificial neural networks--a method for prediction of survival following liver resection for colorectal cancer metastases.

Spelt L, Nilsson J, Andersson R, Andersson B.

Eur J Surg Oncol. 2013 Jun;39(6):648-54. doi: 10.1016/j.ejso.2013.02.024. Epub 2013 Mar 17.

PMID:
23514791

Supplemental Content

Support Center